-
-
-
-
-
-
-
AbbVie (ABBV): New Data Show RINVOQ Demonstrated Superiority Versus DUPIXENT Across Primary and All Secondary Endpoints
-
-
-
-
-
-
-
Gain Therapeutics (GANX) Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287
-
-
-
-
-
-
-
Arrowhead Pharmaceuticals Inc. (ARWR) Initiates Phase 1/2a Study of ARO-CFB
-
-
-
-
-
-
-
Day One Biopharmaceuticals' (DAWN) OJEMDA Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
-
-
-
-
-
-
-
Edgewise Therapeutics Inc. (EWTX) Granted EU Orphan Drug Designations for Sevasemten
-
-
-
-
-
-
-
Neurocrine Biosciences (NBIX) Reports Positive Phase 2 Data for NBI-1065845
-
-
-
-
-
-
-
Legend Biotech (LEGN) Reports CARVYKTI Approved in EU
-
66,892 total articles have been posted to this category.
Sign-up to StreetInsider.com Premium
to see all today's market moving FDA reports.